Adaptin Bio, Inc. (APTN)

Market Cap	57.89M
Revenue (ttm)	n/a
Net Income	-5.40M
EPS	-0.63
Shares Out	9.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	6.27
Previous Close	6.27
Day's Range	6.27 - 6.27
52-Week Range	5.60 - 6.27
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Adaptin Bio

Adaptin Bio, Inc. develops biotechnology products for the treatment of cancer and other diseases. The company develops bispecific antibody-based therapies using its BRiTE Platform technology. Its BRiTE Platform uses fully human bispecific antibodies to redirect patients' T cells to recognize and destroy tumor cells and facilitate the delivery of T cell-targeting agents across the blood-brain barrier. The company's product pipeline includes APTN-101, an EGFRvIII x CD3 bispecific T cell engager designed to redirect T cells against tumors expressi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2021
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: APTN

Financial Performance

Data Sources: S&P Global Market Intelligence and Alpha Vantage

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Alpha Vantage.

Last checked:

Sep 25, 2026

Data Sources Report a data error